The US Government has awarded Derma Sciences a $4.5m grant to pre-clinically investigate the use of DSC127 in the treatment of skin injuries associated with acute radiation exposure.
The 16-month grant was awarded by the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority.
The contract is a part of the deaprtment’s radiological and nuclear threats preparedness strategy, and could be extended for a total of five years with funds of up to $14m.
Derma Sciences had recently reported positive results from Phase II study evaluating DSC127 in diabetic foot ulcer healing.
The results showed that 54% of wounds healed completely in 12 weeks, compared to only 33% of wounds in patients receiving placebo and best standard of care in the intent-to-treat populations.
DSC127 is a novel angiotensin analogue, which has been shown to improve epithelialisation, granulation, vascularisation, and accelerate wound healing in a variety of normal and diabetic animal models.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData